Plaintiffs’ attorneys stepped up pressure on Merck on cases related to its withdrawal of Vioxx, the anti-inflammatory drug, sending the US drugmaker’s shares plummeting again on Monday. 

Investors were spooked again on fears of Merck litigation and increasing scrutiny of its efforts to market Vioxx over the past five years, in spite of lingering questions about its cardiovascular dangers.

Merck voluntarily withdrew the $2.5bn-a-year seller from the market in September after a company study found it doubled the risk of heart attacks and strokes after 18 months continuous use.

Merck has seen one-third of its market capitalisation slashed, about $35bn in market value, since the Vioxx withdrawal on September 30. Its shares fell almost 10 per cent to $28.28 in New York on Monday.

On Friday, the group warned that selective documents protected by court orders barring public release would leak into the public sphere. “Past experience of other companies in such situations suggests that documents will be deliberately presented out of context to advance the interest of the parties who have started Vioxx litigation,” Merck said.

“Merck should come clean with the public,” said Andy Birchfield, of Beasley Allen, and lead attorney in the first Vioxx lawsuit case scheduled for trial next month. “If Merck is concerned about documents selectively being released in a manner taken out of context, the remedy is for Merck to release all documents so the public can evaluate them.”

Mr. Birchfield said on Monday that even “non-confidential” documents show Merck attempted to downplay Vioxx’s cardiovascular risks for years.

He called “ridiculous” the group’s assertion that court-protected documents were being seen and taken out of context.

Continuing scrutiny and attacks on Merck’s motives with Vioxx also obscured some positive clinical study results on an important new product – an experimental vaccine for cervical cancer in women.

Merck on Monday presented results of a study involving almost 2,400 women showing one form of its experimental vaccine prevented pre-cancerous lesions in women.

The vaccine works to prevent infection of the human papillomavirus (HPV). Persistent HPV infection has been linked to the formation of lesions that can become cervical cancer.

The trial, vaccinating for one HPV strain called HPV 16, prevented lesions in 100 per cent of the women and over 48 months prevented persistent HPV infection in 94 per cent.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Merck to pay $830 million to settle investors’ Vioxx...

Merck announced Friday it will pay $830 million to settle investor complaints accusing it of committing...

Merck to pay nearly $1 billion for illegal marketing...

American pharmaceutical company Merck, Sharp & Dohme has agreed to pay $950 million to resolve criminal...

Merck paying more than 3,100 vioxx death claims

Merck & Co. is paying claims by the families of more than 3,100 users of its Vioxx painkiller who...

Settlement limits insurers' claims in Vioxx deal

TRENTON, N.J. (AP) -- Former Vioxx users getting part of a $4.85 billion settlement ending most personal...

Persistence pays in Vioxx litigation

Plaintiffs get close to $5B, but Merck could have done a lot worse. Attorneys who spent nearly one year...

Vioxx settlement payments to begin in August

Merck & Co., manufacturer of Vioxx, announced it will make the first payment of $500 million on Aug....

Wonderful to work with

Beasley Allen did a great job with my case. They were wonderful to work with. They were available by phone when I needed them, treated me with the utmost respect and worked hard on my behalf. If a need arises in the future, I would definitely call on them again.

—Geraldine